Raul R. Rodriguez is the President and Chief Executive Officer at Rigel Pharmaceuticals Inc., a biotechnology company focused on discovering, developing, and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer, and rare immune diseases. Rodriguez has been with Rigel since 2014, initially joining as a board member before ascending to the CEO position in 2016. His leadership has been instrumental in guiding the company through significant milestones, including the successful launch of TAVALISSE® (fostamatinib disodium hexahydrate), the first and only oral spleen tyrosine kinase (SYK) inhibitor approved for the treatment of chronic immune thrombocytopenia (ITP). Before joining Rigel, Rodriguez had a distinguished career spanning over three decades in the pharmaceutical and biotechnology industries. He previously served as the CEO of both Hyperion Therapeutics and Poniard Pharmaceuticals, where he led the companies through pivotal stages of growth and development. Earlier in his career, Rodriguez held various executive roles at Genentech, where he was instrumental in the development and commercialization of several blockbuster drugs. His extensive experience in drug development, strategic planning, and corporate leadership has been a vital asset to Rigel, enabling the company to advance its pipeline and expand its therapeutic offerings. Under Rodriguez's leadership, Rigel has continued to innovate and expand its research and development efforts, with a focus on addressing unmet medical needs in hematology and oncology. His strategic vision and dedication to patient care have fostered a culture of excellence and collaboration within the company. Rodriguez's contributions have not only solidified Rigel's position in the biotechnology sector but have also brought hope to patients suffering from serious and life-threatening conditions.